Atezolizumab

The FDA granted priority review to atezolizumab as adjuvant treatment for certain people with non-small cell lung cancer.

Atezolizumab plus bevacizumab appeared well-tolerated and resulted in a 40% objective response rate among patients with malignant peritoneal mesothelioma, according to phase 2 study results published in Cancer Discovery.

The combination of cabozantinib and atezolizumab prolonged PFS compared with sorafenib among patients with previously untreated advanced hepatocellular carcinoma, according to topline data released by one of the agent’s manufacturers.

In this video, Pasi A. Jänne, MD, PhD, spoke with Healio about data from the IMpower010 trial presented at the virtual ASCO Annual Meeting.

In this video, Roy Herbst, MD, PhD, spoke with Healio about the practice changing IMpower010 trial presented at the virtual ASCO Annual Meeting.

The addition of atezolizumab to chemotherapy and bevacizumab failed to significantly prolong PFS for women with newly diagnosed stage III or stage IV epithelial ovarian cancer, according to a phase 3 study in Journal of Clinical Oncology.

Atezolizumab after surgery and chemotherapy reduced risk for disease recurrence or death among patients with stage II to stage IIIA non-small cell lung cancer, according to research presented during the virtual ASCO Annual Meeting.

The benefit of atezolizumab plus nab-paclitaxel in advanced triple-negative breast cancer appeared limited to patients with PD-L1 immune cell-positive tumors, an exploratory analysis of the IMpassion130 trial showed.

Genentech voluntarily withdrew atezolizumab’s indication in the United States for patients with platinum-treated metastatic urothelial carcinoma.

Neoadjuvant atezolizumab conferred a 21% major pathologic response rate among patients with resectable stage IB to stage IIIB non-small cell lung cancer.